Scientists at CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, working with Government Medical College and Hospital, Nagpur, have developed two India-specific severity scores for sickle cell anaemia: Indian Severity Score 1 (ISS1) and Indian Severity Score 2 (ISS2).
Tested on 171 patients from Nagpur, ISS1 agreed with expert clinical judgement in 82.8% of cases and ISS2 in 85.1%, against 66.7% for the international Paediatric Severity Score (PSS).
ISS1 adds four clinical features to the 12 parameters of PSS; ISS2 drops the four laboratory values, so severity can be graded from clinical signs alone where lab facilities are thin.
The study was funded under the CSIR-Sickle Cell Anaemia Mission and published in the journal eJHaem in May 2026; it came into the news in the first week of October 2026.
An inherited haemoglobin disorder caused by a mutation in the HBB (beta-globin) gene. Red cells turn rigid and sickle-shaped, block small vessels and break down early. It is autosomal recessive: one faulty gene makes a carrier, two cause disease.
Simple Analogy: Round cells roll through a pipe; sickle-shaped ones snag and pile up like a traffic jam.
Eliminate sickle cell anaemia as a public health problem in India by 2047.
Key: Announced in Union Budget 2023-24; launched by the Prime Minister on 1 July 2023 at Shahdol, Madhya Pradesh. Run by the Ministry of Health and Family Welfare under the National Health Mission, with the Ministry of Tribal Affairs. Screening target: 7 crore people aged 0-40 in 17 high-focus states.
Develop affordable diagnostics, patient management tools and therapies for sickle cell anaemia.
Key: Conceived by CSIR in 2018 and led from CSIR-CCMB. It produced a low-cost dried blood spot PCR-based molecular test, validated by ICMR as a screening-cum-confirmation test with 100% sensitivity and specificity. ISS1 and ISS2 come from the same mission.
CSIR laboratory for modern biology; developed ISS1 and ISS2 and the dried blood spot PCR test.
India's largest publicly funded R&D organisation; parent body of CCMB. Functions under the Department of Scientific and Industrial Research, Ministry of Science and Technology.
Apex body for biomedical research; validated the CCMB PCR test.
Lists sickle cell disease among its 21 specified disabilities, alongside thalassaemia and haemophilia under blood disorders. A graded severity score matters because benefits under the Act depend on the assessed extent of disability.
GS Paper 2 > Health; GS Paper 3 > Science and Technology > Biotechnology and indigenous research
General Awareness > Science > Diseases; Research institutes and their locations
An inherited disorder of the structure or production of haemoglobin, such as sickle cell disease and thalassaemia.
An international 12-parameter score for grading sickle cell severity, built on non-Indian patient data.
The standard oral drug in sickle cell disease; it raises fetal haemoglobin and cuts painful crises.